疫苗

Search documents
康希诺跌2.02%,成交额5024.50万元,主力资金净流入293.71万元
Xin Lang Cai Jing· 2025-10-09 02:35
10月9日,康希诺盘中下跌2.02%,截至10:04,报77.91元/股,成交5024.50万元,换手率0.56%,总市值 192.79亿元。 资金流向方面,主力资金净流入293.71万元,特大单买入101.10万元,占比2.01%,卖出0.00元,占比 0.00%;大单买入1010.06万元,占比20.10%,卖出817.45万元,占比16.27%。 截至6月30日,康希诺股东户数1.75万,较上期减少1.92%;人均流通股0股,较上期增加0.00%。2025年 1月-6月,康希诺实现营业收入3.82亿元,同比增长26.00%;归母净利润-1348.54万元,同比增长 94.02%。 分红方面,康希诺A股上市后累计派现1.98亿元。近三年,累计派现0.00元。 责任编辑:小浪快报 康希诺今年以来股价涨27.62%,近5个交易日跌1.38%,近20日跌7.06%,近60日涨30.07%。 资料显示,康希诺生物股份公司位于天津经济技术开发区西区南大街185号西区生物医药园,成立日期 2009年1月13日,上市日期2020年8月13日,公司主营业务涉及研发、生产和商业化符合中国及国际标准 的创新型疫苗企业。主营业 ...
科前生物涨2.00%,成交额3954.01万元,主力资金净流出300.63万元
Xin Lang Zheng Quan· 2025-09-30 06:01
9月30日,科前生物盘中上涨2.00%,截至13:48,报17.83元/股,成交3954.01万元,换手率0.48%,总市 值83.11亿元。 资金流向方面,主力资金净流出300.63万元,特大单买入143.73万元,占比3.64%,卖出293.14万元,占 比7.41%;大单买入384.66万元,占比9.73%,卖出535.88万元,占比13.55%。 科前生物今年以来股价涨28.63%,近5个交易日涨1.54%,近20日跌0.34%,近60日涨11.44%。 资料显示,武汉科前生物股份有限公司位于湖北省武汉市东湖新技术开发区高新二路419号,成立日期 2001年1月11日,上市日期2020年9月22日,公司主营业务涉及兽用生物制品研发、生产、销售及动物防 疫技术服务。主营业务收入构成为:兽用生物制品94.64%,其他4.46%,其他(补充)0.90%。 截至6月30日,科前生物股东户数9484.00,较上期增加19.03%;人均流通股49148股,较上期减少 15.98%。2025年1月-6月,科前生物实现营业收入4.87亿元,同比增长21.67%;归母净利润2.20亿元,同 比增长44.09%。 分红方 ...
环球印务涨2.25%,成交额2459.68万元,主力资金净流入75.91万元
Xin Lang Cai Jing· 2025-09-30 03:27
Company Overview - Xian Global Printing Co., Ltd. is located in Xi'an High-tech Zone, Shaanxi Province, established on June 28, 2001, and listed on June 8, 2016 [2] - The company primarily engages in the design, production, and sales of pharmaceutical paper box packaging products, along with wine, food color boxes, and corrugated cardboard packaging [2] - The revenue composition includes: 48.31% from pharmaceutical and other paper boxes, 35.90% from printing packaging supply chain, 15.04% from internet digital marketing, and 0.75% from sales of scrap materials and property leasing [2] Financial Performance - As of June 30, 2025, the company reported a revenue of 439 million yuan, a year-on-year decrease of 43.53%, and a net profit attributable to shareholders of -3.72 million yuan, a year-on-year decrease of 109.85% [2] - The company has cumulatively distributed 72.57 million yuan in dividends since its A-share listing, with 17.92 million yuan distributed over the last three years [3] Stock Performance - On September 30, the stock price increased by 2.25%, reaching 8.18 yuan per share, with a total market capitalization of 2.618 billion yuan [1] - Year-to-date, the stock price has risen by 7.92%, with a 3.41% increase over the last five trading days, but a decline of 1.80% over the last 20 days and 5.21% over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent appearance on August 4, where it recorded a net buy of -7.94 million yuan [1] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 9.96% to 24,200, with an average of 13,251 circulating shares per person, a decrease of 9.06% [2] - Among the top ten circulating shareholders, Jinyuan Shun'an Yuanqi Flexible Allocation Mixed Fund (004685) is the seventh largest, holding 1.4071 million shares, an increase of 177,100 shares compared to the previous period [3]
万邦德跌2.04%,成交额1.11亿元,主力资金净流入713.63万元
Xin Lang Cai Jing· 2025-09-25 03:33
Core Viewpoint - Wanbangde's stock price has shown significant volatility, with a year-to-date increase of 71.38% but a recent decline of 4.09% over the last five trading days [2] Group 1: Stock Performance - As of September 25, Wanbangde's stock price was 11.02 CNY per share, with a market capitalization of 6.741 billion CNY [1] - The stock has experienced a 17.36% increase over the past 20 days and a 57.65% increase over the past 60 days [2] - The company has appeared on the "龙虎榜" (top trading list) five times this year, with the most recent occurrence on August 27 [2] Group 2: Financial Performance - For the first half of 2025, Wanbangde reported revenue of 579 million CNY, a year-on-year decrease of 23.15%, and a net profit attributable to shareholders of 13.4635 million CNY, down 64.29% year-on-year [2] - The company's main business revenue composition includes 41.63% from medical devices, 24.69% from chemical raw materials and preparations, 19.61% from other goods, and 14.07% from traditional Chinese medicine [2] Group 3: Shareholder Information - As of June 30, the number of shareholders for Wanbangde was 39,300, an increase of 42.08% from the previous period, while the average circulating shares per person decreased by 30.25% to 14,085 shares [2] Group 4: Dividend Information - Since its A-share listing, Wanbangde has distributed a total of 613 million CNY in dividends, with 122 million CNY distributed over the past three years [3]
西藏药业跌2.00%,成交额2.72亿元,主力资金净流出1477.81万元
Xin Lang Zheng Quan· 2025-09-19 06:02
Company Overview - Tibet Pharmaceutical Co., Ltd. is located in Lhasa Economic and Technological Development Zone, Tibet, and was established on July 14, 1999, with its listing date on July 21, 1999. The company primarily engages in pharmaceutical manufacturing, with 99.80% of its revenue coming from drug sales and 0.20% from other sources [1]. Stock Performance - As of September 19, the stock price of Tibet Pharmaceutical fell by 2.00% to 51.34 CNY per share, with a trading volume of 272 million CNY and a turnover rate of 1.62%. The total market capitalization is 16.548 billion CNY [1]. - Year-to-date, the stock has increased by 46.40%, but it has decreased by 9.02% over the last five trading days. In the last 20 days, the stock rose by 13.69%, and over the past 60 days, it increased by 43.49% [1]. Financial Performance - For the first half of 2025, Tibet Pharmaceutical reported a revenue of 1.651 billion CNY, representing a year-on-year growth of 2.23%. However, the net profit attributable to shareholders decreased by 8.96% to 567 million CNY [2]. Shareholder Information - As of June 30, 2025, the number of shareholders for Tibet Pharmaceutical was 45,200, a decrease of 8.08% from the previous period. The average number of circulating shares per person increased by 8.79% to 7,132 shares [2]. - The company has distributed a total of 2.258 billion CNY in dividends since its A-share listing, with 1.580 billion CNY distributed over the last three years [3]. Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited was the seventh-largest circulating shareholder, holding 2.5902 million shares, a decrease of 1.6084 million shares from the previous period. Huaxia Industry Prosperity Mixed Fund (003567) was the tenth-largest circulating shareholder, maintaining its holding of 1.9036 million shares [3].
沃森生物跌2.05%,成交额2.73亿元,主力资金净流出3743.91万元
Xin Lang Cai Jing· 2025-09-19 05:51
Company Overview - Watson Bio, established on January 16, 2001, and listed on November 12, 2010, is located in Kunming, Yunnan Province. The company specializes in the research, production, and sales of vaccine products [1] - The main revenue composition includes self-developed vaccine products (94.82%), intermediate products (4.67%), other (supplement) (0.26%), and technical services (0.24%) [1] Financial Performance - For the first half of 2025, Watson Bio reported a revenue of 1.154 billion yuan, a year-on-year decrease of 19.47%. The net profit attributable to shareholders was 43.16 million yuan, down 74.69% year-on-year [2] - Cumulative cash dividends since the A-share listing amount to 403 million yuan, with 47.98 million yuan distributed over the past three years [3] Stock Performance - As of September 19, Watson Bio's stock price was 11.95 yuan per share, with a market capitalization of 19.112 billion yuan. The stock has decreased by 0.99% year-to-date and by 3.94% over the last five trading days [1] - The stock experienced a net outflow of 37.44 million yuan in principal funds, with significant selling pressure observed [1] Shareholder Structure - As of June 30, 2025, the number of shareholders increased to 117,300, while the average circulating shares per person decreased by 3.88% to 13,268 shares [2] - The largest circulating shareholder is E Fund's ChiNext ETF, holding 40.27 million shares, a decrease of 1.0618 million shares from the previous period [3]
西藏药业跌2.07%,成交额4.03亿元,主力资金净流出5876.25万元
Xin Lang Zheng Quan· 2025-09-17 06:35
Group 1 - The core viewpoint of the news is that Tibet Pharmaceutical's stock has experienced fluctuations, with a recent decline of 2.07% and a year-to-date increase of 48.54% [1] - As of September 17, the stock price is 52.09 yuan per share, with a total market capitalization of 16.79 billion yuan [1] - The company has seen a net outflow of main funds amounting to 58.76 million yuan, with significant selling pressure observed [1] Group 2 - For the first half of 2025, Tibet Pharmaceutical reported a revenue of 1.651 billion yuan, reflecting a year-on-year growth of 2.23%, while the net profit attributable to shareholders decreased by 8.96% to 567 million yuan [2] - The company has distributed a total of 2.258 billion yuan in dividends since its A-share listing, with 1.580 billion yuan distributed over the past three years [3] - As of June 30, 2025, the number of shareholders decreased by 8.08% to 45,200, while the average circulating shares per person increased by 8.79% to 7,132 shares [2]
康希诺跌2.07%,成交额6648.52万元,主力资金净流出616.01万元
Xin Lang Cai Jing· 2025-09-17 02:43
Core Viewpoint - 康希诺's stock price has shown volatility with a year-to-date increase of 33.84%, but recent trading indicates a slight decline in the short term [1][2]. Financial Performance - As of June 30, 康希诺 reported a revenue of 3.82 billion yuan for the first half of 2025, reflecting a year-on-year growth of 26.00% [2]. - The company experienced a net profit loss of 1348.54 million yuan, which is an improvement of 94.02% compared to the previous period [2]. Stock Market Activity - On September 17, 康希诺's stock price decreased by 2.07%, trading at 81.71 yuan per share with a total market capitalization of 202.19 billion yuan [1]. - The stock saw a net outflow of 616.01 million yuan in principal funds, with significant selling pressure from large orders [1]. Shareholder Information - As of June 30, 康希诺 had 17,500 shareholders, a decrease of 1.92% from the previous period [2]. - The average number of circulating shares per shareholder remained at 0 [2]. Dividend Information - 康希诺 has distributed a total of 1.98 billion yuan in dividends since its A-share listing, with no dividends paid in the last three years [3].
The Wrap-Up for Tuesday September 16
Youtube· 2025-09-16 11:32
Group 1: Live Nation and Ticketmaster - The FTC is investigating Live Nation, the parent company of Ticketmaster, regarding its efforts to prevent bots from illegally reselling tickets on its platform, with a decision expected in the coming weeks [1] - Live Nation could face penalties of up to $53,000 for each violation related to this investigation [1] Group 2: Tesla - Tesla shares have increased by 85% since their low in April and are up approximately 3.5% year-to-date, with a pre-market increase of over 2% [5] - The rise in Tesla's stock follows a significant stock buyback by Elon Musk and the introduction of a new incentive package [5]
科前生物跌2.05%,成交额1765.08万元,主力资金净流入297.99万元
Xin Lang Cai Jing· 2025-09-16 02:55
Company Overview - KQ Bio is located in Wuhan, Hubei Province, and was established on January 11, 2001. The company was listed on September 22, 2020. Its main business involves the research, production, and sales of veterinary biological products, as well as animal epidemic prevention technology services [1][2]. - The revenue composition of KQ Bio is as follows: 94.64% from veterinary biological products, 4.46% from other sources, and 0.90% from supplementary services [1]. Financial Performance - As of June 30, 2025, KQ Bio achieved an operating income of 487 million yuan, representing a year-on-year growth of 21.67%. The net profit attributable to shareholders was 220 million yuan, with a year-on-year increase of 44.09% [2]. - Since its A-share listing, KQ Bio has distributed a total of 711 million yuan in dividends, with 488 million yuan distributed over the past three years [2]. Stock Performance - On September 16, KQ Bio's stock price decreased by 2.05%, trading at 18.20 yuan per share, with a total market capitalization of 8.484 billion yuan [1]. - Year-to-date, KQ Bio's stock price has increased by 31.29%. Over the past five trading days, it has decreased by 0.76%, while it has increased by 3.59% over the past 20 days and by 17.42% over the past 60 days [1]. Shareholder Information - As of June 30, 2025, KQ Bio had 9,484 shareholders, an increase of 19.03% from the previous period. The average number of circulating shares per shareholder was 49,148, which decreased by 15.98% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the newest shareholder, holding 2.3577 million shares [2]. Market Position - KQ Bio is classified under the Shenwan industry category of Agriculture, Forestry, Animal Husbandry, and Fishery - Animal Health II - Animal Health III. The company is associated with several concept sectors, including margin trading, synthetic biology, vaccines, small-cap stocks, and in vitro diagnostics [1].